Klaus-Uwe Kirchgaessler

Pirfenidone in patients with unclassifiable progressive fibrosing interstitial lung disease: a double-blind, randomised, placebo-controlled, phase 2 trial

Toby M. Maher, Tamera J. Corte, Aryeh Fischer et al. · The Lancet Respiratory Medicine · 2019 · 630 citations

Medicine, Clinical Sciences, Pharmacotherapy +6

Antacid therapy and disease outcomes in idiopathic pulmonary fibrosis: a pooled analysis

Michael Kreuter, Wim Wuyts, Elisabetta Renzoni et al. · The Lancet Respiratory Medicine · 2016 · 219 citations · Full text

Medicine, Clinical Sciences, Pharmacotherapy +16

Monocyte Count as a Prognostic Biomarker in Patients with Idiopathic Pulmonary Fibrosis

Michael Kreuter, Joyce Lee, Argyrios Tzouvelekis et al. · American Journal of Respiratory and Critical Care Medicine · 2021 · 198 citations · Full text

Veterinary Medicine, Pharmacotherapy, Inflammation +12

Efficacy and safety of sildenafil added to pirfenidone in patients with advanced idiopathic pulmonary fibrosis and risk of pulmonary hypertension: a double-blind, randomised, placebo-controlled, phase 2b trial

Jürgen Behr, Steven D. Nathan, Wim Wuyts et al. · The Lancet Respiratory Medicine · 2020 · 134 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +8

Long-term safety of pirfenidone: results of the prospective, observational PASSPORT study

Vincent Cottin, Dirk Koschel, Andreas Günther et al. · ERJ Open Research · 2018 · 119 citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +14